2024 CSCO非小细胞肺癌指南(晚期部分)解读  

Interpretation on updates of advanced diseases in CSCO non-small cell lung cancer guideline 2024

作　　者：王家乐 邱天羽 崔亚男 任胜祥[1,2] WANG Jiale;QIU Tianyu;CUI Yanan;REN Shengxiang(School of Medicine,Tongji University,Shanghai 200331,China;Department of Medical Oncology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China)

机构地区：[1]同济大学医学院,上海200331 [2]同济大学附属上海市肺科医院肿瘤科,上海200433

出　　处：《同济大学学报（医学版）》2024年第4期465-470,共6页Journal of Tongji University(Medical Science)

基　　金：国家自然科学基金项目(82373319);上海市优秀学术带头人项目(21XD1423200)。

摘　　要：过去一年,晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)多个临床研究报道更新了研究结果,晚期NSCLC治疗迎来了更多治疗选择、更优疗效及安全性。基于2023年3月—2024年2月的证据,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)更新指南为《中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2024》。该版针对晚期部分的更新包括:EGFR敏感突变、EGFR20号外显子插入、ALK融合、ROS1融合、BRAF V600突变、MET 14外显子跳跃突变、RET融合、HER2突变的治疗部分,以及无驱动基因晚期NSCLC免疫单药治疗及抗体偶联药物(antibody-drug conjugate,ADC)部分。本文将对2024年CSCO NSCLC诊疗指南中有关晚期治疗的这些更新进行详细解读。During the past year,significant findings in advanced non-small cell lung cancer(NSCLC)have been reported or updated from various clinical studies,and the treatment of advanced NSCLC has ushered in more therapeutic options with better efficacy and safety.Based on the evidence during March 2023 to February 2024,the Chinese Society of Clinical Oncology(CSCO)has updated the guideline to 2024 edition.The updates in this edition for the advanced NSCLC include sections of the treatment of EGFR-sensitive mutations,EGFR exon 20 insertions,ALK fusions,ROS1 fusions,BRAF V600 mutations,MET 14 exon jumping mutations,RET fusions,and HER2 mutations,as well as sections of the immune monotherapy and antibody-drug conjugate(ADC)for advanced NSCLC with no driver genes.This article will provide a detailed interpretation of these updates in CSCO NSCLC Guidelines regarding 2024.

关 键 词：晚期非小细胞肺癌 CSCO指南 靶向治疗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]